(UroToday.com) BCG is effective in the management of high-risk non-muscle-invasive bladder cancer (NMIBC), but recurrences are frequent. Furthermore, second-line therapies for BCG-unresponsive high-risk NMIBC remain inadequate. Radical cystectomy is the standard of care for patients with BCG-unresponsive high-risk NMIBC, but many patients are unfit for surgery or elect bladder preservation. At the 2021 American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, Dr. Peter Black and colleagues presented the results of their trial evaluating the activity of atezolizumab in BCG-unresponsive high-risk NMIBC.